Medical Oncology

, 36:3 | Cite as

Unraveling KDM4 histone demethylase expression and its association with adverse cytogenetic findings in chronic lymphocytic leukemia

  • Luma Dayane de Carvalho Filiú-Braga
  • Teresa Raquel Tavares Serejo
  • Antonio Roberto Lucena-Araujo
  • Francisco Assis Rocha Neves
  • Juliana Lott de Carvalho
  • Eduardo Magalhaes Rego
  • Felipe Saldanha-AraujoEmail author
Short Communication


The acquisition of complex karyotypes is related to the progression of chronic lymphocytic leukemia (CLL) and patients with this condition have a poor prognosis. Despite recent advances in the classification of prognosis in CLL patients, understanding of the molecular mechanisms that lead to genomic instability and progression of this disease remains inadequate. Interestingly, dysregulated expression of KDM4 members is involved in the progression of several cancer types and plays a role in the DNA damage response; however, the gene expression profile and the importance of KDM4 members in CLL are still unknown. Here, we assessed the gene expression profile of KDM4A, KDM4B, and KDM4C in 59 CLL samples and investigated whether these histone demethylases have any influence on the prognostic markers of this leukemia. KDM4A gene expression was higher in CLL patients as compared with control samples. In contrast, CLL samples showed decreased levels of the KDM4B transcript in relation to control cases, and no difference was detected in KDM4C expression. Furthermore, patients with positive expression of ZAP-70 had lower expression of KDM4B and KDM4C as compared with ZAP-70-negative patients. More importantly, patients with low expression of these histone demethylases had higher leukemic cell numbers and displayed adverse cytogenetic findings and the acquisition of a complex karyotype. The present data clearly show that the expression of KDM4 members is dysregulated in CLL and impact the prognosis of this leukemia. These findings are useful for a better understanding of the impact of epigenetics on CLL progression.


KDM4 Chronic lymphocytic leukemia Prognostic factors ZAP-70 Karyotype 



This work was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), and Fundação de Amparo à Pesquisa do Distrito Federal (FAPDF).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval and informed consent

The study was approved by the Ethical Committee of the Medical School Hospital of Ribeirão Preto, University of São Paulo, Brazil, and samples were collected after informed consent was obtained from patients and health donors.


  1. 1.
    Roos-Weil D, Nguyen-Khac F, Bernard OA. Chronic lymphocytic leukemia: time to go past genomics? Am J Hematol. 2016;91:518–28.CrossRefGoogle Scholar
  2. 2.
    Barrientos JC. Sequencing of chronic lymphocytic leukemia therapies. Hematol Am Soc Hematol Educ Progr. 2016;2016:128–36.CrossRefGoogle Scholar
  3. 3.
    Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–6.CrossRefGoogle Scholar
  4. 4.
    Mayr C, Speicher MR, Kofler DM, Buhmann R, Strehl J, Busch R, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood. 2006;107:742–51.CrossRefGoogle Scholar
  5. 5.
    Højfeldt JW, Agger K, Helin K. Histone lysine demethylases as targets for anticancer therapy. Nat Rev Drug Discov. 2013;12:917–30.CrossRefGoogle Scholar
  6. 6.
    Labbé RM, Holowatyj A, Yang Z-Q. Histone lysine demethylase (KDM) subfamily 4: structures, functions and therapeutic potential. Am J Transl Res. 2013;6:1–15.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Berry WL, Janknecht R. KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res. 2013;73:2936–42.CrossRefGoogle Scholar
  8. 8.
    Young LC, McDonald DW, Hendzel MJ. Kdm4b histone demethylase is a DNA damage response protein and confers a survival advantage following γ-irradiation. J Biol Chem. 2013;288:21376–88.CrossRefGoogle Scholar
  9. 9.
    Khoury-Haddad H, Guttmann-Raviv N, Ipenberg I, Huggins D, Jeyasekharan AD, Ayoub N. PARP1-dependent recruitment of KDM4D histone demethylase to DNA damage sites promotes double-strand break repair. Proc Natl Acad Sci USA. 2014;111:E728–37.CrossRefGoogle Scholar
  10. 10.
    Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, Que TH, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8:1640–5.PubMedGoogle Scholar
  11. 11.
    Carvalho Alves-Silva J, do Amaral Rabello D, Oliveira Bravo M, Lucena-Araujo A, Madureira de Oliveira D, Morato de Oliveira F, et al. Aberrant levels of SUV39H1 and SUV39H2 methyltransferase are associated with genomic instability in chronic lymphocytic leukemia. Environ Mol Mutagen. 2017;58:654–61.CrossRefGoogle Scholar
  12. 12.
    Nabhan C, Raca G, Wang YL. Predicting prognosis in chronic lymphocytic leukemia in the contemporary era. JAMA Oncol. 2015;1:965–74.CrossRefGoogle Scholar
  13. 13.
    Kogure M, Takawa M, Cho H-S, Toyokawa G, Hayashi K, Tsunoda T, et al. Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)/S transition. Cancer Lett. 2013;336:76–84.CrossRefGoogle Scholar
  14. 14.
    Black JC, Manning AL, Van Rechem C, Kim J, Ladd B, Cho J, et al. KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors. Cell. 2013;154:541–55.CrossRefGoogle Scholar
  15. 15.
    Young LC, Hendzel MJ. The oncogenic potential of Jumonji D2 (JMJD2/KDM4) histone demethylase overexpression. Biochem Cell Biol. 2013;91:369–77.CrossRefGoogle Scholar
  16. 16.
    Ouillette P, Collins R, Shakhan S, Li J, Peres E, Kujawski L, et al. Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood. 2011;118:3051–61.CrossRefGoogle Scholar
  17. 17.
    Awwad SW, Ayoub N. Overexpression of KDM4 lysine demethylases disrupts the integrity of the DNA mismatch repair pathway. Biol Open. 2015;4:498–504.CrossRefGoogle Scholar
  18. 18.
    Ishimura A, Terashima M, Kimura H, Akagi K, Suzuki Y, Sugano S, et al. Jmjd2c histone demethylase enhances the expression of Mdm2 oncogene. Biochem Biophys Res Commun. 2009;389:366–71.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Luma Dayane de Carvalho Filiú-Braga
    • 1
  • Teresa Raquel Tavares Serejo
    • 1
  • Antonio Roberto Lucena-Araujo
    • 2
  • Francisco Assis Rocha Neves
    • 1
  • Juliana Lott de Carvalho
    • 3
  • Eduardo Magalhaes Rego
    • 4
  • Felipe Saldanha-Araujo
    • 1
    Email author
  1. 1.Laboratório de Farmacologia MolecularUniversidade de BrasíliaBrasíliaBrazil
  2. 2.Laboratório de HematologiaUniversidade Federal de PernambucoRecifeBrazil
  3. 3.Laboratório de BiotecnologiaUniversidade Católica de BrasíliaBrasíliaBrazil
  4. 4.Laboratório de HematologiaUniversidade de São PauloRibeirão PrêtoBrazil

Personalised recommendations